The impact of age on survival of diffuse large B-cell lymphoma – a population-based study

References

• Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: WHO; 2008. p. 439.
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 14:1002–6.
   Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;4:235–42.
   Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open- label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;11:1013–22.
   Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;14:987–94.
   Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123:837–42.
   PubMed Web of Science ®Google Scholar
• Varga C, Holcroft C, Kezouh A, Bucatel S, Johnson N, Petrogiannis-Haliotis T, et al. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: A population based study. Leuk Lymphoma 2014;55:533–7.
   PubMed Web of Science ®Google Scholar
• Lobetti-Bodoni C, Rancoita PM, Montoto S, Lopez- Guillermo A, Conconi A, Coutinho R, et al. The importance of age in prognosis of follicular lymphoma: Clinical features and life expectancy of patients younger than 40 years. ASH Annual Meeting Abstracts 2011;21:1593.
   Google Scholar
• Sjoberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973–2009. Blood 2012;4:990–6.
   Web of Science ®Google Scholar
• Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011;12:1888–90.
   Web of Science ®Google Scholar
• Thunberg U, Amini RM, Linderoth J, Roos G, Enblad G, Berglund M. BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution. Br J Haematol 2009;6:683–4.
   Web of Science ®Google Scholar
• Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012;8:1882–7.
   Web of Science ®Google Scholar
• Szekely E, Hagberg O, Arnljots K, Jerkeman M. Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, IPI and extranodal presentation: A population based Swedish Lymphoma Registry study. Leuk Lymphoma 2014;55:1838–43 .
   PubMed Web of Science ®Google Scholar
• Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961;6:101–21.
   PubMedGoogle Scholar
• Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed 2006;3:272–8.
   Web of Science ®Google Scholar
• Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, et al. Impact of rituximab on treatment outcomes of patients with diffuse large B-cell lymphoma: A population-based analysis. Br J Haematol 2012;4:481–8.
   Web of Science ®Google Scholar
• Jayasekara H, Karahalios A, Juneja S, Thursfield V, Farrugia H, English DR, et al. Incidence and survival of lymphohematopoietic neoplasms according to the World Health Organization classification: A population-based study from the Victorian Cancer Registry in Australia. Leuk Lymphoma 2010;3:456–68.
   Web of Science ®Google Scholar
• Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson PO. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma – a population-based study. Leuk Lymphoma 2007;4:736–45.
   Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;2:105–16.
   Web of Science ®Google Scholar
• Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 2012;91: 1383–91.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 6:2977–83.
   Web of Science ®Google Scholar
• Pulte D, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. Leuk Lymphoma 2013;5:979–85.
   Web of Science ®Google Scholar
• Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011;1:139–47.
   Web of Science ®Google Scholar
• Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppa S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 2009;8:1094–101.
   Web of Science ®Google Scholar
• Boslooper K, Kibbelaar R, Storm H, Veeger NJ, Hovenga S, Woolthuis G, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: A population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 2014;55:526–32.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;22:5027–33.
   Web of Science ®Google Scholar